Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the medical Journal “Nature Medicine”, a widely respected publication in the medical community, where he says researchers found that the gene TUSC2, the lead component of the drug, acts as a tumor-preventing gene.
0 Comments